Polymorphisms in the genes related to angiogenesis are associated with uterine cervical cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 7, 2013, Pages 1198-1204

  Ramos Flores, Christian ^a   Romero Gutiérrez, Teresa ^a   Delgado Enciso, Iván ^a,b   Maldonado, Gabriela Enríquez ^c   Plascencia, Víctor Montaño ^c   Vazquez Vuelvas, Oscar F ^a,d   Quintero Ramos, Antonio ^e   Mejía, Roberto Chaparro ^f   Espinoza Gomez, Francisco ^a   Baltazar Rodriguez, Luz M ^a   Valdez Velazquez, Laura L ^a  

^a UNIVERSIDAD DE COLIMA   (Mexico)

^b Cancerology State Institute   (Mexico)

^c Pathologic Anatomy Laboratory   (Mexico)

^d UNIVERSIDAD AUTÓNOMA DE COAHUILA   (Mexico)

^e UNIVERSITY OF GUADALAJARA   (Mexico)

^f Hospital Regional Universitario   (Mexico)

Author keywords

PAI 1; Polymorphism; TGF 1; Uterine cervical cancer; VEGF

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CANCER GENETICS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEXICO; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEXUAL BEHAVIOR; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CERVIX UTERI; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MEXICO; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84884528630     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31829f4c6f     Document Type: Article

References (30)

1. Castellanos M. Cáncer cérvicouterino y el VPH. Opciones de detecció n. Rev Fac Med UNAM. 2006;46:44.
2. Prescrire Int. Human papillomavirus: often harmless but in some cases carcinogenic. Prescrire Int. 2007;16:115-119.
3. Tee YT, Wang PH, Tsai HT, et al. Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia. J Surg Oncol. 2012;106:204-208.
4. Wang Y, Yang H, Li L, et al. An updated meta-analysis on the association of TGF-beta1 gene promoter -509C/T polymorphism with colorectal cancer risk. Cytokine. 2013;61:181-187.
5. Chae YS, Kim JG, Sohn SK, et al. Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer. J Korean Med Sci. 2008;23:421-427.
6. Palmirotta R, Ferroni P, Savonarola A, et al. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res. 2009;124:403-408.
7. Pappot H, Gardsvoll H, Romer J, et al. Plasminogen activator inhibitor type 1 in cancer: Therapeutic and prognostic implications. Biol Chem Hoppe Seyler. 1995;376:259-267.
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
9. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350-1358.
10. Jiménez G, Villalobos M, Jiménez E, et al. Determinación de la efectividad de cinco protocolos de extracción de ADN a partir de material parafinado para estudios moleculares. Rev Med Univ Costa Rica. 2007;1:10-19.
11. Festa A, D'Agostino R, Rich SS, et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: The Insulin Resistance Atherosclerosis Study. Circulation. 2003;107:2422-2427.
12. Duffy MJ, Duggan C. The urokinase plasminogen activator system: A rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem. 2004;37:541-548.
13. Zorio E, Gilabert-Estelles J, Espana F, et al. Fibrinolysis: The key to new pathogenetic mechanisms. Curr Med Chem. 2008;15:923-929.
14. Eriksson P, Kallin B, van't Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A. 1995;92:1851-1855.
15. Halamkova J, Kiss I, Pavlovsky Z, et al. Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients. Neoplasma. 2013;60:151-159.
16. Chang HR, Yang SF, Tsai JP, et al. Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus. Clin Chim Acta. 2011;412:322-326.
17. Hazelbag S, Kenter GG, Gorter A, et al. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int J Cancer. 2004;112:1020-1028.
18. Bao G, Wang M, Guo S, et al. Vascular endothelial growth factor +936 C/T gene polymorphism and glioma risk in a Chinese Han population. Genet Test Mol Biomarkers. 2011;15:103-106.
19. Wu X, Li D, Liu Z, et al. Vascular endothelial growth factor 1498C/T, 936C/T polymorphisms associated with increased risk of colorectal adenoma: A Chinese case-control study. Mol Biol Rep. 2011;38:1949-1955.
20. Kim YH, Kim MA, Park IA, et al. VEGF polymorphisms in early cervical cancer susceptibility, angiogenesis, and survival. Gynecol Oncol. 2010;119:232-236.
21. Yang JW, Hutchinson IV, Shah T, et al. Gene polymorphism of vascular endothelial growth factor -1154 G9A is associated with hypertensive nephropathy in a Hispanic population. Mol Biol Rep. 2011;38:2417-2425.
22. Jin Q, Hemminki K, Grzybowska E, et al. Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer. 2004;112:94-99.
23. Guo W, Dong Z, Guo Y, et al. Polymorphisms of transforming growth factor-beta1 associated with increased risk of gastric cardia adenocarcinoma in north China. Int J Immunogenet. 2011;38:215-224.
24. Su Z-g, Wen F-q, Feng Y-l, et al. Transforming growth factor-A1 gene polymorphisms associated with chronic obstructiv pulmonary disease in Chinese population. Acta PharmacolSin. 2005;26:714-720.
25. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005;23:2078-2093.
26. Guan X, Zhao H, Niu J, et al. The VEGF -634G9C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol. 2009;9:77.
27. Horn LC, Pippig S, Raptis G, et al. Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix. Aust N Z J Obstet Gynaecol. 2002;42:383-386.
28. Saito H, Tsujitani S, Oka S, et al. The expression of transforming growth factor-A1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer. 1999;86:1455-1462.
29. Bensen JT, Hsu FC, Brown WM, et al. Association analysis of the plasminogen activator inhibitor-1 4G/5G polymorphism in Hispanics and African Americans: The IRAS family study. Hum Hered. 2004;57:128-137.
30. Datta PK, Blake MC, Moses HL. Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-betaYinduced physical and functional interactions between Smads and Sp1. J Biol Chem. 2000;275: 40014-40019.